Arcutis Biotherapeutics (ARQT) Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Which has more risk and volatility, ARQT or BBIO?

Arcutis Biotherapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Which has better earnings and valuation, ARQT or BBIO?

Arcutis Biotherapeutics has higher revenue and earnings than BridgeBio Pharma. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$212.82M	8.13	-$262.14M	-$1.04	-13.95
BridgeBio Pharma	$127.42M	50.24	-$535.76M	-$3.53	-9.55

Do institutionals and insiders believe in ARQT or BBIO?

99.8% of BridgeBio Pharma shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is ARQT or BBIO more profitable?

Arcutis Biotherapeutics has a net margin of -140.97% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-140.97%	-119.11%	-45.95%
BridgeBio Pharma	-241.44%	N/A	-75.69%

Do analysts recommend ARQT or BBIO?

Arcutis Biotherapeutics presently has a consensus price target of $18.80, suggesting a potential upside of 29.57%. BridgeBio Pharma has a consensus price target of $57.09, suggesting a potential upside of 69.36%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
BridgeBio Pharma	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

Does the media prefer ARQT or BBIO?

In the previous week, BridgeBio Pharma had 8 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 18 mentions for BridgeBio Pharma and 10 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.63 beat BridgeBio Pharma's score of 0.91 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BridgeBio Pharma	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Does the MarketBeat Community favor ARQT or BBIO?

BridgeBio Pharma received 107 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 72.47% of users gave BridgeBio Pharma an outperform vote while only 67.92% of users gave Arcutis Biotherapeutics an outperform vote.

Company	Underperform	Outperform
Arcutis Biotherapeutics	Outperform Votes 72 67.92%	Underperform Votes 34 32.08%
BridgeBio Pharma	Outperform Votes 179 72.47%	Underperform Votes 68 27.53%

Summary

BridgeBio Pharma beats Arcutis Biotherapeutics on 10 of the 18 factors compared between the two stocks.